Eli Lilly and Boehringer Ingelheim slash German investments after Berlin pushes health reform savings
Eli Lilly halved its Alzey plant investment and Boehringer Ingelheim scrapped €900 million in planned spending, both citing Berlin's proposed health reform as the trigger.
Two cancellations in one day
Within hours on the same day, two of the world's largest pharmaceutical manufacturers announced they were scaling back German investment plans. The US group Eli Lilly said it would invest only half of the roughly $2.5 billion (€2.2 billion) it had previously earmarked for a new production site in Alzey, Rhineland-Palatinate. The family-owned German firm Boehringer Ingelheim disclosed it was dropping €900 million in investments planned for 2027 to 2030 across its domestic sites. Both companies pointed to the federal government's health reform package, which is due for its first Bundestag reading next Thursday.
Germany will fall to last place among European markets in supporting our industry.
The reform that triggered the pullback
The draft law, shepherded by Health Minister Nina Warken (CDU) under Chancellor Friedrich Merz (CDU), aims to close a widening gap in the statutory health insurance system (GKV). The GKV faces a shortfall of more than €15 billion that could grow beyond €40 billion by 2030. The bill proposes a general price freeze on medicines until 2030, dynamic manufacturer rebates that would rise annually, and the possibility of discount contracts for innovative drugs that critics say would undermine intellectual property protection.
With those dynamic manufacturer rebates it is practically impossible to do any planning at all, because these rebates change every year. Moreover, one must assume that in future they will only rise.
Industry warns of a systemic shift
Jasmina Kirchhoff, a pharmaceutical expert at the Institut der deutschen Wirtschaft (IW), described the twin announcements as "clear warning shots" for Germany as a pharma location. She argued that the US market is undergoing a complete realignment and that pressure from Asia is rising, while some countries have already raised their drug budgets in response to US policy. Germany, she said, is doing "exactly the opposite." Kirchhoff called for all relevant ministries to sit down together and resolve what she termed a serious goal conflict between health policy and economic policy.
Roche's Germany chief Hagen Pfundner put the trade-off bluntly: the industry had planned billions in investment, and now it is being asked to pay billions. A manager at another large pharma company told WirtschaftsWoche it was becoming ever harder to explain why a big international group should invest in Germany when capital flows to the jurisdictions with the best conditions.
The pharmaceutical industry had planned billions in investment in Germany. Now we are supposed to pay billions.
Political reaction in Rhineland-Palatinate
The state most directly affected is Rhineland-Palatinate, home to both the Eli Lilly site in Alzey and Boehringer Ingelheim's headquarters. State premier Gordon Schnieder (CDU) said he was "in great concern" and announced he would raise the issue in the Bundesrat next week, using the legislative process to seek allies among fellow state premiers. His office confirmed he is in contact with both companies, with Chancellor Merz, Minister Warken, and CDU/CSU parliamentary group leader Jens Spahn. Local CDU Bundestag member Jan Metzler also signalled support for the pharma firms.
I am in great concern.
Insurers push back
The statutory health insurers rejected the industry's stance. A spokesperson for the GKV umbrella organisation accused the companies of coercion, arguing that the reform is necessary to stabilise the system. The Berliner Zeitung noted that the German health system is one of the most expensive and least efficient in the world, with more than €300 billion flowing through it annually from employer and employee contributions. The paper described the industry's lobbying as a well-oiled machine that treats the GKV as a "cash cow."
- Chancellor Scholz attends Eli Lilly groundbreaking in Alzey, calling it possibly the largest pharma investment since reunification.
- Ampel coalition streamlines clinical-trial rules and health data access; wave of investments by Lilly, Sanofi, Roche, Daiichi Sankyo.
- Health Minister Warken receives expert commission recommendations and introduces draft health reform bill in Bundestag.
- Boehringer Ingelheim announces it will not invest planned €900 million in German sites for 2027–2030.
- Eli Lilly says it will halve its Alzey investment to about €1.1 billion; both firms cite the health reform as reason.
- Bundestag scheduled to hold first reading of the health reform bill.
A deal that soured
The mood swing is stark. In April 2024, then-Chancellor Olaf Scholz (SPD) travelled to Alzey for the Eli Lilly groundbreaking, calling it possibly the largest single pharma investment in Germany since reunification. The Ampel coalition had streamlined clinical-trial regulations and improved access to health data, triggering a wave of investments by Lilly, Sanofi in Frankfurt, Roche in Penzberg, and Daiichi Sankyo in Pfaffenhofen. Now the black-red coalition under Merz is pursuing savings that the industry views as a breach of that implicit bargain. The Frankfurter Allgemeine quoted Goethe's Egmont — "himmelhoch jauchzend, zu Tode betrübt" — to capture the industry's trajectory from euphoria to despair.
